02139nas a2200265   4500000000100000008004100001260001900042653002300061653002900084653002200113653001200135100001600147700001900163700001600182700001900198700001200217700002000229700001800249245007000267856009800337300001000435490000700445520140700452022001401859       2026                            d  c09/2026bLepra10aInfectious disease10ahaematologic alterations10aMultidrug therapy10aDapsone1 aOktariana D1 aChristianti FA1 aArgentina F1 aRahadiyanto KY1 aLiana P1 aHafizzanovian H1 aAseptianova A00aHaematologic changes associated with multidrug therapy in leprosy  uhttps://leprosyreview.org/admin/public/api/lepra/website/getDownload/6a9f9f59afaac15f573b7552  a1 - 90 v973 a<p>Leprosy is a chronic infectious condition caused by Mycobacterium leprae, which predominantly involves the skin and peripheral nervous system. Multidrug therapy (MDT), consisting of dapsone, rifampicin, and clofazimine, remains the primary treatment. Although effective, MDT may induce haematologic changes, particularly due to the oxidative effects of dapsone. This study aimed to evaluate haematologic changes among leprosy patients receiving MDT. A longitudinal retrospective study was conducted at Mohammad Hoesin Hospital, Palembang. Fifty-five leprosy patients were included. Most patients were male, young adults (18–44 years), and classified as multibacillary, with the majority receiving the regular MDT regimen. Notable haematologic changes were identified following MDT administration, with significant changes observed in haemoglobin, mean corpuscular volume, and mean corpuscular haemoglobin. Normocytic normochromic anaemia was the most frequently encountered morphological pattern. Despite these haematologic shifts, no significant association was found between the type of MDT regimen and the incidence of anaemia. Overall, the findings suggest that MDT may contribute to red cell changes reflected in Hb, MCV, and MCH values. Regular haematologic monitoring during therapy is therefore recommended to support early recognition and management of treatment-associated anaemia.</p>
  a2162-8807